NCT06439901 Optimizing Bronchopulmonary Cancer Screening
| NCT ID | NCT06439901 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Curie |
| Condition | Bronchopulmonary Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-01-27 |
| Primary Completion | 2033-02-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2025-01-27 with a primary completion date of 2033-02-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to evaluate the feasibility of performing a first screening for bronchopulmonary cancer by thoracic scanner in a French cohort within a dedicated, effective and structured network in the pilot centers participating in the study.
Eligibility Criteria
Inclusion Criteria: * Participant aged 50 to 74. * Resident in the Île-de-France region. * Active smoker or quit smoker for 10 years or less: 1. more than 10 cigarettes a day for more than 30 years, 2. more than 15 cigarettes a day for more than 25 years. * The participant has been informed and has signed the consent form. * Social Security System affiliation. * Willingness to participate in a smoking cessation program, if currently smoking. Exclusion Criteria: * Active cancer or a history of cancer in remission for less than 5 years (except basal cell carcinoma of th skin or epithelioma in situ of the uterine cervix). * Presence of symptoms suggestive of bronchopulmonary cancer. Participants with these symptoms require immediate diagnostic investigations and are therefore not eligible for screening. * Weight \>= 140 kg. * Severe comorbidity contraindicating therapeutic options or invasive thoracic diagnostic investigations. * Inability to climb two flights of stairs without stopping. * A thoracic CTscan performed within the previous year. * Persons deprived of liberty or under guardianship. * Impossibility to undergo the medical monitoring of the trial for geographical, social or psychological reasons.
Contact & Investigator
Catherine DANIEL, MD
STUDY DIRECTOR
Institut Curie
Frequently Asked Questions
Who can join the NCT06439901 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 74 Years, studying Bronchopulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06439901 currently recruiting?
Yes, NCT06439901 is actively recruiting participants. Contact the research team at catherine.daniel@curie.fr for enrollment information.
Where is the NCT06439901 trial being conducted?
This trial is being conducted at Bobigny, France, Gentilly, France, Issy-les-Moulineaux, France, Malakoff, France and 5 additional locations.
Who is sponsoring the NCT06439901 clinical trial?
NCT06439901 is sponsored by Institut Curie. The principal investigator is Catherine DANIEL, MD at Institut Curie. The trial plans to enroll 500 participants.